5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.28▲ | 2.26▲ | 2.26▲ | 2.10▲ | 2.63▼ |
MA10 | 2.28▲ | 2.26▲ | 2.24▲ | 2.40▼ | 2.41▼ |
MA20 | 2.27▲ | 2.22▲ | 2.11▲ | 2.74▼ | 2.70▼ |
MA50 | 2.26▲ | 2.08▲ | 2.27▲ | 2.47▼ | 2.72▼ |
MA100 | 2.13▲ | 2.38▼ | 2.62▼ | 2.70▼ | 1.61▲ |
MA200 | 2.21▲ | 2.78▼ | 2.49▼ | 3.16▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | 0.000▼ | 0.035▲ | -0.078▼ | -0.060▼ |
RSI | 54.589▲ | 59.841▲ | 58.974▲ | 47.762▼ | 47.132▼ |
STOCH | 70.076 | 59.940 | 77.110 | 31.445 | 29.485 |
WILL %R | -29.630 | -16.667▲ | -8.696▲ | -64.186 | -73.980 |
CCI | 61.292 | 26.702 | 68.437 | -36.035 | -83.779 |
Tuesday, December 03, 2024 05:04 PM
FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that its strategic partner, Genting ...
|
Wednesday, November 27, 2024 05:24 PM
Celularity (CELU) received notification from the Nasdaq Listing Qualifications department stating that the company does not comply with the ...
|
Wednesday, November 27, 2024 02:19 PM
Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
05/12/24 | 2.40 | 2.50 | 2.12 | 2.32 | 306,880 |
04/12/24 | 1.88 | 2.20 | 1.88 | 2.18 | 205,206 |
03/12/24 | 1.85 | 2.05 | 1.77 | 2.00 | 232,736 |
02/12/24 | 2.02 | 2.08 | 1.8564 | 1.97 | 106,079 |
29/11/24 | 2.00 | 2.11 | 1.92 | 2.04 | 195,136 |
27/11/24 | 2.85 | 2.934 | 1.55 | 2.01 | 1,743,600 |
26/11/24 | 3.00 | 3.01 | 2.71 | 2.85 | 50,313 |
25/11/24 | 2.70 | 3.20 | 2.69 | 3.00 | 149,799 |
22/11/24 | 2.84 | 2.95 | 2.58 | 2.76 | 105,024 |
21/11/24 | 2.93 | 2.9799 | 2.72 | 2.85 | 97,131 |
|
|
||||
|
|
||||
|
|